Equities research analysts predict that Thermo Fisher Scientific Inc. (NYSE:TMO) will post sales of $5.62 billion for the current quarter, Zacks Investment Research reports. Seven analysts have made estimates for Thermo Fisher Scientific’s earnings, with the highest sales estimate coming in at $5.67 billion and the lowest estimate coming in at $5.54 billion. Thermo Fisher Scientific posted sales of $4.77 billion during the same quarter last year, which would indicate a positive year over year growth rate of 17.8%. The firm is expected to report its next quarterly earnings report on Wednesday, April 25th.
On average, analysts expect that Thermo Fisher Scientific will report full year sales of $5.62 billion for the current fiscal year, with estimates ranging from $23.47 billion to $23.67 billion. For the next year, analysts forecast that the firm will post sales of $24.82 billion per share, with estimates ranging from $24.49 billion to $25.95 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Thermo Fisher Scientific.
Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, January 31st. The medical research company reported $2.79 earnings per share for the quarter, topping analysts’ consensus estimates of $2.66 by $0.13. The business had revenue of $6.05 billion for the quarter, compared to analyst estimates of $5.72 billion. Thermo Fisher Scientific had a return on equity of 16.01% and a net margin of 10.64%. The company’s quarterly revenue was up 22.1% compared to the same quarter last year. During the same period in the prior year, the company earned $2.41 EPS.
TMO has been the topic of a number of research analyst reports. Leerink Swann restated an “outperform” rating and issued a $239.00 target price (up from $200.00) on shares of Thermo Fisher Scientific in a research note on Thursday, February 1st. They noted that the move was a valuation call. Deutsche Bank set a $226.00 target price on Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Thursday, October 26th. Evercore ISI initiated coverage on Thermo Fisher Scientific in a research note on Wednesday, January 3rd. They issued an “outperform” rating and a $220.00 target price on the stock. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $215.00 target price on the stock in a research note on Tuesday, October 31st. Finally, Bank of America upped their target price on Thermo Fisher Scientific from $235.00 to $250.00 and gave the stock a “buy” rating in a research note on Thursday, February 1st. Two analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $220.50.
In related news, CEO Marc N. Casper sold 50,000 shares of the stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $191.74, for a total transaction of $9,587,000.00. Following the completion of the sale, the chief executive officer now directly owns 302,577 shares in the company, valued at approximately $58,016,113.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Stephen Williamson sold 5,000 shares of the stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $209.26, for a total value of $1,046,300.00. Following the sale, the chief financial officer now owns 30,741 shares of the company’s stock, valued at $6,432,861.66. The disclosure for this sale can be found here. Insiders have sold a total of 95,327 shares of company stock valued at $19,470,342 over the last 90 days. 0.49% of the stock is currently owned by company insiders.
A number of hedge funds have recently modified their holdings of TMO. Mutual of America Capital Management LLC lifted its holdings in Thermo Fisher Scientific by 2.1% in the 2nd quarter. Mutual of America Capital Management LLC now owns 47,728 shares of the medical research company’s stock worth $8,327,000 after buying an additional 977 shares during the period. Americafirst Capital Management LLC purchased a new stake in Thermo Fisher Scientific in the 3rd quarter worth approximately $876,000. Rockland Trust Co. lifted its holdings in Thermo Fisher Scientific by 7.3% in the 4th quarter. Rockland Trust Co. now owns 62,332 shares of the medical research company’s stock worth $11,836,000 after buying an additional 4,221 shares during the period. San Francisco Sentry Investment Group CA purchased a new stake in Thermo Fisher Scientific in the 2nd quarter worth approximately $1,451,000. Finally, Huntington National Bank lifted its holdings in Thermo Fisher Scientific by 2.4% in the 3rd quarter. Huntington National Bank now owns 195,348 shares of the medical research company’s stock worth $36,959,000 after buying an additional 4,655 shares during the period. Institutional investors own 86.54% of the company’s stock.
Thermo Fisher Scientific (NYSE:TMO) opened at $207.84 on Wednesday. The firm has a market capitalization of $84,453.64, a PE ratio of 22.22, a price-to-earnings-growth ratio of 1.54 and a beta of 1.11. The company has a quick ratio of 0.92, a current ratio of 1.35 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific has a one year low of $151.74 and a one year high of $226.44.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, April 16th. Stockholders of record on Thursday, March 15th will be given a dividend of $0.17 per share. The ex-dividend date is Wednesday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. This represents a $0.68 annualized dividend and a dividend yield of 0.33%. Thermo Fisher Scientific’s dividend payout ratio is 10.71%.
COPYRIGHT VIOLATION NOTICE: This article was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/21/thermo-fisher-scientific-inc-tmo-expected-to-post-quarterly-sales-of-5-62-billion.html.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Get a free copy of the Zacks research report on Thermo Fisher Scientific (TMO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.